Publication | Closed Access

Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B

Cost-effectiveness AnalysisHepatologyHealth EconomicsHealth PolicyViral HepatitisHepatitis BHepatitisOutcomes ResearchTreatment OptionAustralian PatientsChronic Hepatitis BPharmacotherapyPharmacoeconomicsCost EffectivenessMedicine